BridgeMD
New treatment option for Sickle Cell Disease
Official title Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life.
ClinicalTrials.gov ID: NCT06823219
What this study is testing
- What it's testing
- Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Due to anaemia and multiple pulmonary, cardiac, endothelial, muscle, and metabolic dysfunctions, fatigue and poor physical capacity are common in SCD patients and constitute the primary reason for a sedentary lifestyle.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 15 and older
You may be able to join if
- Aged over 15 years and 3 months
- Male or female
- Patients with sickle cell disease (HbSS or HbS-βthal0)
- Affiliated to a social security system
- Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved
You likely can't join if
- Patient whose adherence to the protocol is unlikely according to the investigator
- Patients who already partake in regular physical activity (more than 1 hour of moderate-intensity physical activity per week)
- Patients with a chronic inflammatory and/or infectious pathology
- Patients with an intercurrent condition unresolved for less than a month
- Patients hospitalised for cardiac decompensation during the last 12 months
- Patients on anticoagulant treatment or with a pacemaker/defibrillator
See the full eligibility criteria
- Aged over 15 years and 3 months
- Male or female
- Patients with sickle cell disease (HbSS or HbS-βthal0)
- Affiliated to a social security system
- Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved
- Patients in stabilised condition at the start of the experiment: at least 1 month after an acute chronic event or at least 3 months after a blood transfusion.
- Patients hospitalised for vaso-occlusive crisis at least once in the last 3 years
- Patient whose adherence to the protocol is unlikely according to the investigator
- Patients who already partake in regular physical activity (more than 1 hour of moderate-intensity physical activity per week)
- Patients with a chronic inflammatory and/or infectious pathology
- Patients with an intercurrent condition unresolved for less than a month
- Patients hospitalised for cardiac decompensation during the last 12 months
- Patients on anticoagulant treatment or with a pacemaker/defibrillator
- Pregnant patients / breastfeeding woman
- Patients deprived of liberty by judicial or administrative decision or patient under guardianship
- Patients unable to understand the objectives and conditions of the study and unable to give cons
The study team makes the final eligibility decision.
Where it's taking place
- Créteil, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 15 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Créteil, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.